MA42377A - Anticorps se liant à tau - Google Patents

Anticorps se liant à tau

Info

Publication number
MA42377A
MA42377A MA042377A MA42377A MA42377A MA 42377 A MA42377 A MA 42377A MA 042377 A MA042377 A MA 042377A MA 42377 A MA42377 A MA 42377A MA 42377 A MA42377 A MA 42377A
Authority
MA
Morocco
Prior art keywords
tau
antibodies
bonding
antibodies bonding
Prior art date
Application number
MA042377A
Other languages
English (en)
Inventor
Terence Seward Baker
Jean-Philippe Courade
Patrick Downey
Robert Anthony Griffin
David Edward Ormonde Knight
Georges Mairet-Coello
David James Mcmillan
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53524640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA42377(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of MA42377A publication Critical patent/MA42377A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
MA042377A 2015-07-06 2016-07-05 Anticorps se liant à tau MA42377A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15175522 2015-07-06

Publications (1)

Publication Number Publication Date
MA42377A true MA42377A (fr) 2018-05-16

Family

ID=53524640

Family Applications (2)

Application Number Title Priority Date Filing Date
MA41670A MA41670A1 (fr) 2015-07-06 2016-07-05 Anticorps se liant a tau
MA042377A MA42377A (fr) 2015-07-06 2016-07-05 Anticorps se liant à tau

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA41670A MA41670A1 (fr) 2015-07-06 2016-07-05 Anticorps se liant a tau

Country Status (26)

Country Link
US (4) US10287343B2 (fr)
EP (1) EP3319983B1 (fr)
JP (3) JP6630426B2 (fr)
KR (2) KR102770650B1 (fr)
CN (1) CN107849104B (fr)
AR (1) AR105267A1 (fr)
AU (1) AU2016289755C1 (fr)
CA (1) CA2991451A1 (fr)
CL (1) CL2018000043A1 (fr)
CO (1) CO2017012971A2 (fr)
EA (1) EA037092B1 (fr)
EC (1) ECSP18000887A (fr)
IL (1) IL256685B (fr)
MA (2) MA41670A1 (fr)
MX (1) MX2017015817A (fr)
MY (1) MY193677A (fr)
PE (1) PE20180481A1 (fr)
PH (1) PH12017502207B1 (fr)
SG (1) SG10202010735PA (fr)
SM (1) SMT202600068T1 (fr)
TN (1) TN2017000539A1 (fr)
TW (1) TWI745295B (fr)
UA (1) UA124616C2 (fr)
UY (1) UY36773A (fr)
WO (1) WO2017005734A1 (fr)
ZA (1) ZA201800027B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA126272C2 (uk) 2015-06-05 2022-09-14 Дженентек, Інк. Антитіло проти тау-білка та спосіб його застосування
MA41670A1 (fr) 2015-07-06 2018-05-31 Ucb Biopharma Sprl Anticorps se liant a tau
TN2017000543A1 (en) 2015-07-06 2019-04-12 Ucb Biopharma Sprl Tau-binding antibodies
CA3045294A1 (fr) 2016-12-07 2018-06-14 Genentech, Inc. Anticorps anti-tau et methodes d'utilisation
MX2019006334A (es) 2016-12-07 2019-08-01 Genentech Inc Anticuerpos antitau y métodos de uso.
EP3824906A1 (fr) 2016-12-21 2021-05-26 Amgen Inc. Formulations d'anticorps anti-tnf alpha
JP2020508054A (ja) 2017-02-17 2020-03-19 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 抗タウ抗体及びその使用方法
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
UA129617C2 (uk) 2017-10-16 2025-06-18 Еісаі Р Енд Д Менеджмент Ко., Лтд. Антитіло до тау та його застосування
US12509505B2 (en) 2018-12-13 2025-12-30 INSERM (Institute National de la Santé et de la Recherche Médicale) Anti Tau SVQIVYKPV epitope single domain antibody
CA3147548A1 (fr) * 2019-08-13 2021-02-18 Randall Bateman Procedes de detection d'isoformes tau de mtbr et leur utilisation
CA3167317C (fr) 2020-02-12 2025-05-27 Eli Lilly And Company Cristallisation d'anticorps ou de fragments de liaison à l'antigène
US20230265175A1 (en) 2020-06-25 2023-08-24 Merck Sharp & Dohme Llc High affinity antibodies targeting tau phosphorylated at serine 413
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
KR20250069606A (ko) 2022-09-15 2025-05-19 보이저 테라퓨틱스, 인크. 타우 결합 화합물
IL320461A (en) * 2022-11-14 2025-06-01 Washington University St Louis Methods for detecting MTBR-CSF Tau and its uses
WO2025122634A1 (fr) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions et méthodes pour le traitement de troubles liés à la protéine tau
WO2025171285A1 (fr) * 2024-02-09 2025-08-14 University Of Notre Dame Du Lac Protéomimétiques tau
WO2025196217A1 (fr) 2024-03-21 2025-09-25 UCB Biopharma SRL Traitement de tauopathies avec des anticorps se liant à la protéine tau

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
AU2004253738A1 (en) 2003-07-01 2005-01-13 Ucb Pharma S.A. Modified antibody Fab fragments
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
CN1721437A (zh) * 2004-07-13 2006-01-18 中南大学 一种与Tau蛋白相关的多肽抗原及抗体
EP2500352A1 (fr) 2005-08-19 2012-09-19 Abbott Laboratories Immunoglobuline à double domaine variable et ses utilisations
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
JP5592792B2 (ja) 2007-09-26 2014-09-17 ユセベ ファルマ ソシエテ アノニム 二重特異性抗体の融合体
CN101307108B (zh) * 2008-06-25 2012-04-04 南京川博生物技术有限公司 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途
LT2334705T (lt) 2008-09-26 2017-03-27 Ucb Biopharma Sprl Biologiniai produktai
EP2346906A4 (fr) 2008-10-15 2013-04-24 Angiochem Inc Conjugués d'agonistes de glp-1 et leurs utilisations
JP5759379B2 (ja) 2008-12-05 2015-08-05 アンジオケム インコーポレーテッド ニューロテンシンまたはニューロテンシンアナログおよびその使用
US20110288009A1 (en) 2008-12-05 2011-11-24 Angiochem Inc. Leptin and leptin analog conjugates and uses thereof
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
ES2667258T3 (es) 2009-09-10 2018-05-10 Ucb Biopharma Sprl Anticuerpos multivalentes
US20120277158A1 (en) 2009-10-06 2012-11-01 Angiochem Inc. Compositions and methods for the transport of therapeutic agents
EP2625198B1 (fr) 2010-10-07 2015-07-22 AC Immune S.A. Anticorps dirigés contre tau phosphorylée
US8940272B2 (en) * 2010-10-11 2015-01-27 University Of Zurich Human anti-tau antibodies
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
SG10201912964PA (en) 2011-09-19 2020-02-27 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
US20140294724A1 (en) * 2011-10-24 2014-10-02 Intellect Neurosciences, Inc. Compositions and methods for treatment of proteinopathies
SI2776466T1 (sl) 2011-11-11 2017-12-29 Ucb Biopharma Sprl Protitelesa, ki se vežejo na albumin in njihovi vezavni fragmenti
DK2794654T3 (da) 2011-12-20 2019-08-05 Janssen Biotech Inc Anti-phf-tau-antistoffer og deres anvendelser
SG10201913370PA (en) * 2012-07-03 2020-03-30 Univ Washington Antibodies to tau
SI2885010T1 (sl) 2012-08-16 2020-07-31 Ipierian, Inc. Metode zdravljenja tauopatije
BR112015014751A8 (pt) 2012-12-21 2018-01-16 Biogen Int Neuroscience Gmbh anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos.
CA2874083C (fr) * 2014-12-05 2024-01-02 Universite Laval Polypeptides liant le tdp-43 utiles pour le traitement de maladies neurodegeneratives
MA41670A1 (fr) 2015-07-06 2018-05-31 Ucb Biopharma Sprl Anticorps se liant a tau
TN2017000543A1 (en) 2015-07-06 2019-04-12 Ucb Biopharma Sprl Tau-binding antibodies

Also Published As

Publication number Publication date
JP7413448B2 (ja) 2024-01-15
WO2017005734A1 (fr) 2017-01-12
JP2022141689A (ja) 2022-09-29
PE20180481A1 (es) 2018-03-07
EP3319983A1 (fr) 2018-05-16
US10889640B2 (en) 2021-01-12
BR112017028102A2 (en) 2018-09-04
US20180201666A1 (en) 2018-07-19
NZ738058A (en) 2021-07-30
IL256685A (en) 2018-03-29
CL2018000043A1 (es) 2018-05-18
JP6630426B2 (ja) 2020-01-15
KR20250027278A (ko) 2025-02-25
KR102770650B1 (ko) 2025-02-19
IL256685B (en) 2022-02-01
JP7100008B2 (ja) 2022-07-12
HK1246804A1 (zh) 2018-09-14
PH12017502207A1 (en) 2018-06-11
US11732034B2 (en) 2023-08-22
US20230416350A1 (en) 2023-12-28
MA41670A1 (fr) 2018-05-31
EA037092B1 (ru) 2021-02-04
SG10202010735PA (en) 2020-11-27
US20190284267A1 (en) 2019-09-19
CN107849104B (zh) 2021-08-27
CN107849104A (zh) 2018-03-27
US20210115121A1 (en) 2021-04-22
SMT202600068T1 (it) 2026-03-09
CA2991451A1 (fr) 2017-01-12
EP3319983C0 (fr) 2026-01-28
TWI745295B (zh) 2021-11-11
TW201713689A (zh) 2017-04-16
UY36773A (es) 2017-01-31
EA201890172A1 (ru) 2018-10-31
US10287343B2 (en) 2019-05-14
UA124616C2 (uk) 2021-10-20
KR20180025962A (ko) 2018-03-09
TN2017000539A1 (en) 2019-04-12
AR105267A1 (es) 2017-09-20
AU2016289755A1 (en) 2018-01-04
CO2017012971A2 (es) 2018-03-09
JP2020055849A (ja) 2020-04-09
AU2016289755B2 (en) 2020-12-03
JP2018524001A (ja) 2018-08-30
MY193677A (en) 2022-10-25
AU2016289755C1 (en) 2021-08-19
ECSP18000887A (es) 2018-03-31
EP3319983B1 (fr) 2026-01-28
PH12017502207B1 (en) 2022-08-10
MX2017015817A (es) 2018-04-10
ZA201800027B (en) 2019-06-26

Similar Documents

Publication Publication Date Title
MA42380A (fr) Anticorps se liant à tau
MA42377A (fr) Anticorps se liant à tau
FR24C1056I2 (fr) Nouveaux anticorps anti-pd-l1
MA51734A (fr) Anticorps se liant à gprc5d
FR25C1022I1 (fr) Anticorps anti-pd-1
EP3512549A4 (fr) Anticorps se liant à cd3
EP3498840A4 (fr) Anticorps anti-lag-3
EP3423089A4 (fr) Anticorps anti-tigit
EP3334757A4 (fr) Anticorps anti-tigit
MA42626A (fr) Nouveaux anticorps anti-pd-1
EP3297671A4 (fr) Anticorps anti-ror1
EP3334824A4 (fr) Anticorps anti-pd-1
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
EP3349787A4 (fr) Anticorps cd47 thérapeutiques
EP3307777A4 (fr) Nouveaux anticorps anti-pd-l1
MA53297A (fr) Anticorps anti-icos
MA52643A (fr) Anticorps se liant spécifiquement au tl1a
EP3492591A4 (fr) Anticorps anti-b7-h4
MA49289A (fr) Anticorps se liant à steap-1
EP3383915A4 (fr) Anticorps anti-pd-1
EP3526247A4 (fr) Anticorps anti-il1-rap
EP3399992A4 (fr) Anticorps autoréticulants
IL263272A (en) Anti-coagulation factor xi antibodies
EP3484919A4 (fr) Anticorps anti-bêta-amyloïde
EP2949750A4 (fr) Peptide liant les anticorps